<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343575</url>
  </required_header>
  <id_info>
    <org_study_id>28330</org_study_id>
    <nct_id>NCT02343575</nct_id>
  </id_info>
  <brief_title>Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU</brief_title>
  <official_title>Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delirium is the most often encountered psychiatric diagnosis in the general hospital, with
      incidence up to 85% in the intensive care unit (ICU) setting and with significant
      consequences on patients' morbidity and mortality. Currently, although not FDA approved,
      antipsychotics are often considered the first-line pharmacological treatment. However, there
      can be limitations to their use, including side effects or lack of efficacy. Valproic acid
      (VPA) is one of the alternatives at times used in such patients which from limited case
      series data appears to be helpful and tolerated. VPA can provide relief from agitation that
      poses a threat to the safety and recovery of the patient. Moreover, mechanistically it
      addresses the neurochemical and cellular abnormalities inherent in delirium (it has
      NMDA-antagonist, anti-dopaminergic, GABAergic,anti-inflammatory, anti-apoptotic, and histone
      deacetylase inhibitor properties, among others). The purpose of this study is to evaluate the
      efficacy and tolerability of the VPA in the first known to us randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to investigate the efficacy and tolerability of scheduled VPA as
      compared to placebo with as needed basis (PRN) haloperidol (as a back-up in both arms) for
      treatment of hyperactive or mixed delirium. Patients will be randomized to scheduled VPA or
      placebo (normal saline) and both arms will have flexible PRN dosing of haloperidol. Thus, the
      investigators plan to learn the time to delirium resolution in patients treated with VPA
      versus placebo; percentage of patients responding to VPA versus placebo; tolerability of VPA
      versus placebo. If addition of scheduled VPA proves to shorten time to delirium resolution as
      compared to placebo, lead to less use of haloperidol, and/or have fewer side effects, it
      would provide a very important addition to our limited evidence-based repertoire of delirium
      treatment. Moreover, this pilot study would then pave the way for the bigger randomized
      control trial powered to detect its effect size.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We did not recruit the research assistant and terminated the study
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Delirium Resolution</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Delirium resolution was defined as three negative Confusion Assessment Method (CAM) assessments, performed by nurses every 12 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of as Needed Anti-psychotic Agent</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Amount of Haldol administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects From Medications</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Side effects may have included liver function test (LFT) increase, platelet decrease, bleeding, or QTc prolongation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Delirium as Measured by the Intensive Care Delirium Screening Checklist (ICDSC) Delirium Severity Scale</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>The items include the assessment of: (1) consciousness ( deep sedation/coma, agitation, normal wakefulness, or light sedation); (2) inattention; (3) disorientation; (4) hallucination, delusion, or psychosis; (5) psychomotor agitation or retardation; (6) inappropriate speech or mood; (7) sleep-wake cycle disturbances; and (8) fluctuation of symptomatology. The maximum score is eight; scores of â‰¥4 indicate the presence of delirium and score zero is indicate not in delirium. Each item is scored 0-8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Stay</measure>
    <time_frame>During expected average hospitalization (of 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>During expected average hospitalization (of 1 month)</time_frame>
    <description>Participation in the study ended once delirium was resolved and the patient was off study drug. This outcome presents the total length of hospital stay, which may have been longer than participation in the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hyperactive Delirium</condition>
  <condition>Mixed Delirium</condition>
  <arm_group>
    <arm_group_label>Valproic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start:
VPA PO/NGT 500 mg BID
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
Rescue at all stages: HAL IV 2-5 mg Q4hr PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: PO/NGT BID
Rescue: HAL IV 2-5 mg Q4hr PRN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>1.
Start:
VPA PO/NGT 500 mg BID
2.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
3.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
4.If need to increase in 24 or more hours:
VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS</description>
    <arm_group_label>Valproic Acid</arm_group_label>
    <other_name>VPA</other_name>
    <other_name>Valproate</other_name>
    <other_name>Depakote</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500 mg matched to VPA BID PO/NGT</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Valproic Acid</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 18 years of age and older

          -  admitted to surgical ICU

          -  diagnosed with hyperactive or mixed delirium

        Exclusion Criteria:

          -  hypoactive delirium

          -  primary team does not think patient is appropriate to participate

          -  no oral access (PO or NGT)

          -  non-English speaking

          -  contraindication to study medications

          -  pregnant women or woman of child-bearing age not on documented contraception

          -  QTc = or greater than 480

          -  hepatic dysfunction

          -  decreased platelets or platelet dysfunction

          -  bleeding disorder, current major bleeding

          -  history of NMS, epilepsy, or PD

          -  diagnosis of schizophrenia, bipolar disorder or schizoaffective disorder

          -  on warfarin or carbapenems

          -  delirium due to alcohol withdrawal

          -  treated with antipsychotics for more than 48 hours prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yelizaveta Sher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose R Maldonado, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <results_first_submitted>May 31, 2019</results_first_submitted>
  <results_first_submitted_qc>May 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Yelizaveta Sher</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperactive delirium</keyword>
  <keyword>Mixed delirium</keyword>
  <keyword>Anti-psychotic</keyword>
  <keyword>Haldol</keyword>
  <keyword>Valproic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02343575/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valproic Acid</title>
          <description>Participants received Valproic Acid (VPA) and flexible haloperidol as needed.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valproic Acid</title>
          <description>Participants received VPA and flexible haloperidol as needed.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Delirium Resolution</title>
        <description>Delirium resolution was defined as three negative Confusion Assessment Method (CAM) assessments, performed by nurses every 12 hours.</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Delirium Resolution</title>
          <description>Delirium resolution was defined as three negative Confusion Assessment Method (CAM) assessments, performed by nurses every 12 hours.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of as Needed Anti-psychotic Agent</title>
        <description>Amount of Haldol administered.</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of as Needed Anti-psychotic Agent</title>
          <description>Amount of Haldol administered.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects From Medications</title>
        <description>Side effects may have included liver function test (LFT) increase, platelet decrease, bleeding, or QTc prolongation.</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects From Medications</title>
          <description>Side effects may have included liver function test (LFT) increase, platelet decrease, bleeding, or QTc prolongation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LFT increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc prolongation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Delirium as Measured by the Intensive Care Delirium Screening Checklist (ICDSC) Delirium Severity Scale</title>
        <description>The items include the assessment of: (1) consciousness ( deep sedation/coma, agitation, normal wakefulness, or light sedation); (2) inattention; (3) disorientation; (4) hallucination, delusion, or psychosis; (5) psychomotor agitation or retardation; (6) inappropriate speech or mood; (7) sleep-wake cycle disturbances; and (8) fluctuation of symptomatology. The maximum score is eight; scores of â‰¥4 indicate the presence of delirium and score zero is indicate not in delirium. Each item is scored 0-8.</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Delirium as Measured by the Intensive Care Delirium Screening Checklist (ICDSC) Delirium Severity Scale</title>
          <description>The items include the assessment of: (1) consciousness ( deep sedation/coma, agitation, normal wakefulness, or light sedation); (2) inattention; (3) disorientation; (4) hallucination, delusion, or psychosis; (5) psychomotor agitation or retardation; (6) inappropriate speech or mood; (7) sleep-wake cycle disturbances; and (8) fluctuation of symptomatology. The maximum score is eight; scores of â‰¥4 indicate the presence of delirium and score zero is indicate not in delirium. Each item is scored 0-8.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of ICU Stay</title>
        <time_frame>During expected average hospitalization (of 1 month)</time_frame>
        <population>Data were not collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of ICU Stay</title>
          <population>Data were not collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Participation in the study ended once delirium was resolved and the patient was off study drug. This outcome presents the total length of hospital stay, which may have been longer than participation in the study.</description>
        <time_frame>During expected average hospitalization (of 1 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valproic Acid</title>
            <description>Participants received VPA and flexible haloperidol as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Participation in the study ended once delirium was resolved and the patient was off study drug. This outcome presents the total length of hospital stay, which may have been longer than participation in the study.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Valproic Acid</title>
          <description>Participants received VPA and flexible haloperidol as needed.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received VPA placebo and flexible haloperidol as needed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>QTc prolongation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study terminated early and did not meet its planned sample size of 30 participants, leading to a small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yelizaveta Sher, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-736-0459</phone>
      <email>ysher@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

